Serum adropin as a potential renoprotective factor in diabetic kidney disease: evidence from a Chinese elderly cohort and an experimental mouse model - Takeaways - MDSpire

Serum adropin as a potential renoprotective factor in diabetic kidney disease: evidence from a Chinese elderly cohort and an experimental mouse model

  • By

  • Ruohan Jiang

  • Xianfa Xuan

  • Jing Ye

  • Xiulan Guo

  • Hanxiang Jiang

  • Siyu Zhang

  • Zhaoxia Ruan

  • Ting Wu

  • Jia Wang

  • Chen Tang

  • Yiqin Zhang

  • Jie Zhang

  • July 13, 2026

Share

  • 1

    Higher serum adropin levels were inversely associated with prevalent diabetic kidney disease (DKD) in a community-based cohort of 6,896 participants.

  • 2

    Among participants free of DKD at baseline, higher baseline adropin was linked to a lower risk of incident DKD over a median follow-up of 6.09 years.

  • 3

    Restricted cubic spline analyses indicated a linear cross-sectional association and a non-linear prospective association between adropin and DKD.

  • 4

    In an STZ-induced DKD mouse model, serum adropin levels declined during disease progression, and adropin treatment improved renal injury indicators.

  • 5

    The study combined cross-sectional and longitudinal analyses with experimental validation to explore the role of adropin in DKD.

Original Source(s)

Serum adropin as a potential renoprotective factor in diabetic kidney disease: evidence from a Chinese elderly cohort and an experimental mouse model

  • by Ruohan Jiang, Xianfa Xuan, Jing Ye, Xiulan Guo, Hanxiang Jiang, Siyu Zhang, Zhaoxia Ruan, Ting Wu, Jia Wang, Chen Tang, Yiqin Zhang, Jie Zhang

  • July 13, 2026

Related Content

Linking glucose metabolism to arterial stiffness and blood pressure in non-diabetic adults: the mediating role of FGF21

Exercise rejuvenates the “muscle-heart” crosstalk: skeletal muscle-derived exosomal miRNAs in cardiac aging

GLP-1 RAs Associated With Small ION Risk Increase

In an observational US target trial emulation, glucagon-like peptide-1 receptor agonist initiation was associated with about 3 to 4 more ischemic optic neuropathy cases per 10,000 patients over 18 months than two comparator drug classes.